Study Links GLP-1 Jabs to Less Sick Leave

Weight-loss injections may do more than shrink waistlines: new UK research suggests they also slash sickness absence and lighten the load on an NHS already stretched thin.

A study tracking patients prescribed GLP-1 jabs over nine months found sickness days fell by nearly half, while absences lasting five days or more dropped by more than 50%. The findings add a new layer to the debate around obesity treatment, shifting the focus from individual weight loss to wider effects on workplaces, primary care, and emergency services.

The research suggests GLP-1 treatment may reach far beyond weight management, cutting time off work and easing pressure across the health system.

Analysis linked to the study indicates broader access to the drugs could reduce A&E attendance among obese patients by about a quarter and free up nearly 10 million GP appointments. Those projections remain estimates, but they point to a potentially significant public health payoff if the results hold up at scale. For a service under relentless demand, even modest reductions in avoidable visits can ripple across the system.

The study arrives as demand for GLP-1 medicines grows and policymakers weigh who should get access, at what cost, and with what medical support. Supporters argue the drugs could help tackle obesity-related illness before it drives people into emergency care. Critics will likely press for more evidence on long-term outcomes, affordability, and whether benefits persist once treatment ends.

What happens next matters well beyond one class of drugs. Health leaders and ministers now face a practical question: whether expanding access to GLP-1 treatment can deliver measurable savings for the NHS as well as better health for patients. If further research confirms these results, the case for treating obesity as a system-wide economic and healthcare issue—not just a personal one—will only grow stronger.